Our news feed highlights the developments that matter most, paired with short commentary from TAG and partners on what each headline means for communities, policymakers, and researchers. Check back regularly for updates and perspectives on where TB vaccine development stands, what emerging developments mean, and what needs to happen next.
Erin McConnell, Treatment Action GroupAs TB Vaccines move from clinical trials into arms, manufacturing and supply chain questions will dominate discussions around pricing and access. The early interest from Indonesia’s Bio Farma to serve as a regional manufacturer ofthe M72/AS01E tuberculosis vaccine candidate, should it prove successful, brings manufacturing closer to the communities that need it most and positions Indonesia – one of the highest burden regions for TB – at the center of new TB vaccine supply chains.
Erin McConnell, Treatment Action GroupThe Wellcome-funded Tuberculosis Integrated Model-Based Evidence and Recommendations (TIMBER) study will identify evidence to inform policy recommendations supportive of future TB vaccines. TIMBERs work may prove particularly useful in advocacy directing national expenditure on TB vaccines as they become available.
Shaun Palmer, IAVILate pipeline vaccine candidates are changing the landscape of the TB prevention field, paving a new path to ending TB and saving millions of lives in the process.
Mike Frick, Treatment Action GroupFollowing disappointing results around preventing TB disease in adults and adolescents in April 2026, a genetically-modified recombinant of BCG, VPM1002 proved inferior to the traditional BCG vaccine at preventing TB infections in newborns.
Taran Deol, Treatment Action GroupEarlier this year, the Gates Medical Research Institute (Gates MRI) named the Serum Institute of India (SII) as the commercial manufacturer of M72/AS01E, a closely watched TB vaccine candidate now in Phase 3 trials. The announcement was significant, particularly after GSK, the vaccine’s original developer, did not take it forward following promising Phase 2b results in 2018. Gates MRI and SII will now begin technology transfer, with SII committing more than $100 million of its own resources to strengthen manufacturing readiness.
Shaun Palmer, IAVISince it was established in 2023, the TB Vaccine Accelerator Council has continued to coordinate early preparation work necessary to ensure the smooth introduction of potential new TB vaccines. At the most recent meeting in May of 2026, the council established a formal working group dedicated to country readiness, advocacy, and community partnership that centers TB affected communities as leaders in all country level preparedness activities.


